medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 6

<< Back Next >>

Ann Hepatol 2014; 13 (6)

Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment

Maor Y, Schapiro JM, Bashari D, Martinowitz U

Language: English
References: 26
Page: 753-761
PDF size: 103.62 Kb.


ABSTRACT

Background/Purpose. Hepatitis C (HCV) is a major cause of morbidity and mortality in haemophilia patients who received clotting factor concentrates before the availability of virus-inactivated factors in the mid- 1980s. Recently, it has been suggested that anti-HCV treated patients, particularly those achieving a sustained virological response (SVR) have an improved outcome. We sought to examine the survival of treated and untreated HCV-infected haemophilia patients. Material and methods. We studied overall and liver-related survival of patients with haemophilia and other congenital bleeding disorders between 2000 and 2010. The outcome was compared in 3 sub-groups: HCV mono-infected (N = 127), HCV/HIV co-infected (N = 28), and patients with either HCV-antibodies negative or persistent HCV RNA-negative (referred to as non-infected) (N = 45). Sixty-two (40%) (HCV and HCV/HIV) patients underwent anti-HCV treatment with an SVR rate of 40.3%. Results. Overall and liver-related 10-year survival were: 82.1 and 89.3%, 95.3 and 99.2 and 100% for HCV/HIV co-infected, HCV mono-infected and non-infected haemophilia patients, respectively (p = 0.015 and 0.023 for comparisons of HCV/HIV vs. HCV; p = 0.003 for comparison of HCV/HIV and non-infected). One HCV mono-infected and 3 co-infected patients died of end-stage liver disease (2 underwent liver transplantation). There was no survival benefit from anti-HCV treatment or from attaining of an SVR. Only clinically suspected cirrhosis remained as an independent predictor of survival. Conclusion. The prognosis of haemophilia patients who acquired HCV/HIV co-infection is worse than that of HCV mono-infected or non-infected or haemophiliacs. This is mainly due to liver-related mortality. Anti-HCV treatment or SVR had no observable impact on survival rate.


REFERENCES

  1. Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988; 2: 782-5.

  2. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-51.

  3. Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia 2002; 8: 322-9.

  4. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.

  5. Lichterfeld M, Schmeisser N, Qurishi N, Vogel M, Brackmann HH, Spengler U, Rockstroh JK. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005; 50: 221-8.

  6. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIVHCV co-infection. Haemophilia 2009; 15: 552-8.

  7. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004; 38(Suppl. 2): S104-S108.

  8. Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, van Erpecum KJ, et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667-71.

  9. Maor Y, Bashari D, Kenet G, Lalezari S, Lubetsky A, Luboshitz J, Schapiro JM, et al. Hepatitis C at the Israeli National Hemophilia Center. Haemophilia 2006; 12: 68-74.

  10. Franchini M, Rossetti G, Tagliaferri A, Capra F, de Maria E, Pattacini C, Lippi G, et al. The natural history of hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 2001; 98: 1836--41.

  11. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.

  12. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, et al; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.

  13. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-8.

  14. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.

  15. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  16. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  17. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.

  18. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, Castille JM, et al. Applicability and precautions of use of liver injury biomarker FibroTest™. A reappraisal at 7 years of age. BMC Gastroenterol 2011; 11: 39.

  19. Fried MW, Kroner BL, Preiss LR, Wilhelmsen K, Goedett JJ. Multicenter Hemophilia Cohort Study. Hemophilic siblings with chronic hepatitis C: familial aggregation of sponta761 Natural history of hepatitis C-infected haemophilia patients. , 2014; 13 (6): 753-761 neous and treatment-related viral clearance. Gastroenterology 2006; 131: 57-64.

  20. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.

  21. Fransen van de Putte DE, Fischer K, de Knegt RJ, Posthouwer D, van Erpecum KJ, Biesma DH, Mauser-Bunschoten EP. Beneficial effect of successful HCV treatment in patients with inherited bleeding disorders, assessed by liver stiffness measurements. Haemophilia 2012; 18: e266- e272.

  22. Maor Y, Schapiro JM, Bashari D, Lurie Y, Safadi R, Segol O, Paritsky M, et al. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience. Haemophilia 2008; 14: 336-42.

  23. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 61: 1191-200.

  24. Wilde JT, Mutimer D, Dolan G, Millar C, Watson HG, Yee TT, Makris M. UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. Haemophilia 2011; 17: e877-e883.

  25. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.

  26. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al; ADVANCE Study Team Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.




2020     |     www.medigraphic.com